Results 141 to 150 of about 786,314 (373)

Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System

Drug Discoveries & Therapeutics
Fosfomycin, with its unique mechanism of action, has emerged as a promising option for clinicians to combat antimicrobial resistance and the limited availability of effective drugs, which has led to an increase in associated adverse events (AEs). This study aims to explore the AEs caused by fosfomycin through data mining of the US FDA Adverse Event ...
Luxuan, Yang, Wenyong, Zhang, Xiujuan, Shen, Meiqin, Liu, Meiying, Wu, Dan, Xiao   +5 more
openaire   +2 more sources

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

Learning signals of adverse drug-drug interactions from the unstructured text of electronic health records. [PDF]

, 2013
Drug-drug interactions (DDI) account for 30% of all adverse drug reactions, which are the fourth leading cause of death in the US. Current methods for post marketing surveillance primarily use spontaneous reporting systems for learning DDI signals and ...
Bauer-Mehren, Anna, Harpaz, Rave, Iyer, Srinivasan V, Lependu, Paea, Shah, Nigam H   +4 more
core   +5 more sources

Patient safety indicators for England from hospital administrative data: case-control analysis and comparison with US data [PDF]

, 2008
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.The Healthcare Commission ...
Bremner, SA, Cooper, J, Raleigh, VS, Scobie, S   +3 more
core   +2 more sources

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS

Frontiers in Pharmacology
ObjectiveTo mine and analyze adverse events (AEs) related to proteasome inhibitors in multiple myeloma based on the FDA Adverse Event Reporting System (FAERS), providing references for rational clinical medication.MethodsAE data related to multiple ...
Yuan Peng, Yuan Peng, Yuying Zhou, Kaisen Shu, Xu Jia, Yan Zhong   +5 more
doaj   +1 more source

VA releases adverse event data: Clinicians must report to nationwide system [PDF]

, 2000
Nancy Tarleton Landis
openalex   +1 more source

Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline [PDF]

Clinical Gastroenterology and Hepatology, 2018
Victor Chedid, Priya Vijayvargiya, Michael Camilleri   +2 more
openaire   +3 more sources

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, C. Andrew Stewart, Christopher M. Jewell, Metin Kurtoglu, Miloš D. Miljković, Tuan Vu, Tahseen Mozaffar, James F. Howard Jr, the MG‐001 Study Group   +10 more
wiley   +1 more source

Concomitant Risk Factors in Reports of Torsades de Pointes Associated with Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting System [PDF]

, 2002
Douglas Shaffer, Sarah Singer, Joyce A. Korvick, Peter K. Honig   +3 more
openalex   +1 more source

Change in Cognition Following Ischaemic Stroke

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline can occur following ischaemic stroke. How cognition changes over time and associations with cognitive change are poorly understood. This study aimed to explore these issues over 2 years following ischaemic stroke.
Wenci Yan, Terence Quinn, Alex McConnachie, Niall Broomfield, Yun Wong, David Dickie, Kirsten Forbes, Matthew Walters, Jesse Dawson   +8 more
wiley   +1 more source